Form 4 for PFE Pfizer
Accepted 2023-02-28 00:00:00 ET · period of report 2023-02-25 · accession 0001225208-23-002918 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-02-28 | 2023-02-25 | PFE | BOURLA ALBERT | COB, CEO, Dir | F - Tax | $41.75 | -43.4K | 309.1K | -12% | -$1.81M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-25 | F | D | 43,419 | $41.75 | 309,058 | D | — | — | (F1) The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the settlement of stock units from previously exercised stock appreciation rights (including dividend equivalents thereon). (F2) Price is the closing price of Pfizer common stock on February 24, 2023. |